Table 3 Clinical, biological, radiological characteristics and outcome of PD + and PD- COVID-19 patients

Age (median, IQR)—yr

64 (55–76)

66 (56–84)

0.494

Male sex—no. (%)

24 (60)

19 (48)

0.444

Time from onset of symptoms to DE-CTPA, days (median, IQR)

14 (7–18)

10 (7–14.5)

0.130

Time from admission to DE-CTPA, days (median, IQR)

1 (0–7)

0 (0–2)

0.045

Disease extent assessed on CT lung images

 < 10%—no. (%) (limited extent)

1 (3)

3 (11)

0.295

 10–50%—no. (%) (regrouping mild and moderate extent)

17 (43)

13 (48)

0.799

 > 50%—no. (%) (regrouping severe and diffuse extent)

22 (55)

11 (41)

0.321

Anticoagulant treatment prior to DE-CTPA

 Preventive dosage—no. (%)

13 (33)

8 (30)

1

 Curative dosage—no. (%)

5 (13)

2 (7)

0.693

Oxygen-support at DE-CTPA

 Invasive ventilation- no. (%)

0 (0)

1 (4)

0.023

 High-flow oxygen (≥ 6 l/min)—no. (%)

14 (35)

7 (26)

0.592

 Low-flow oxygen (< 6 l/min and room air)—no. (%)

26 (65)

19 (70)

0.792

Highest oxygen-support during hospital stay

 Invasive ventilation- no. (%)

9 (23)

3 (11)

0.335

 High-flow oxygen (≥ 6 l/min)—no. (%)

14 (35)

9 (33)

1

 Low-flow oxygen (< 6 l/min and room air)—no. (%)

17 (43)

15 (56)

0.328

Biological characteristics

 D-Dimer level just prior to CTPA—median (IQR) ng/mL

1340 (910–2625)

1590 (1140–2142)

0.340

 Highest level of D-dimer during hospitalization – median (IQR) mg/L

1760 (1173–4085)

2221 (1445–3433)

0.305

 Highest level of CRP during hospitalization – median (IQR) mg/L

146 (75–194)

135 (62–206)

0.944

Prognosis

 Duration of hospital admission (alive patients)- days (median, IQR)

14 (8–23)

9 (4–17)

0.117

 Deaths—no. (%)

3 (8)

6 (22)

0.142